C2CD2

Across TCGA pan-cancer cohorts, C2CD2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C2CD2 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher C2CD2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated C2CD2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where C2CD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.809	0.375	.003	19	view →
CCRCC	DFS	Tertile	All	0.903	0.709	.030	4	view →
HNSC	DFS	Median	III,IV	0.906	1.000	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

C2CD2–LUAD (OS)

Open the LUAD breakdown →